Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

11 May 2021

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID..

10 May 2021

BioNTech Announces First Quarter 2021 Financial Results and Corporate Update

10 May 2021

BioNTech to Establish Regional Headquarters for South East Asia and First mRNA ..

Press releases (more)

Upcoming Events

May 18, 2021 from 1:00 PM to 1:45 PM EDT

Berenberg USA Conference 2021

May 26, 2021 from 8:00 AM to 8:45 AM EDT

UBS Global Healthcare Virtual Conference

June 1, 2021 from 11:00 AM to 11:25 AM EDT

Jefferies Virtual Healthcare Conference

Upcoming events (more)

Stock Quote

May 15, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.